CD274 and metastatic melanoma: In the 10 years since the first ICI, Ipilimumab was approved by the FDA for unresectable or metastatic melanoma, numerous clinical studies have demonstrated that ICIs provide substantial survival benefits to patients in some cancer subtypes such as Hodgkin's lymphoma, Merkel cell carcinoma, desmoplastic melanoma, or at the tumors with high PD‐L1 expression, MSIH/pMMR, and high TMB molecular phenotypes.10, 11